About us

OMIX SCIENCE is an AI-driven medical company, leveraging large models to offer personalized health prediction and disease intervention. Our technology research and development follow the path of “BT+MT+IT+AI” (Biotechnology + Medical Technology + Information Technology + Artificial Intelligence), forming a cross-disciplinary innovative technology. Our R&D capabilities have global competitiveness, aligning with the strategic directions of next-generation information infrastructure and the biopharmaceutical industry. Additionally, our solutions empower the silver economy. OMIX collaborates with leading enterprises and industrial funds in upstream and downstream sectors, aiming to build a world-class innovative “artificial intelligence + early detection of major complex diseases + aging intervention technology” scientific innovation ecosystem and an advanced industrial cluster.

OMIX is founded by top global university graduates and industry experts with pioneering and emerging research capabilities. Our team qualifies for national and provincial high-level talent programs. Currently, we have three national-level high-caliber talents, ten provincial-level high-caliber talents, and a twenty-person team from Harvard and other top institutions. Within the year, we plan to recruit an additional five to ten students from top universities including Harvard, MIT, and Stanford, ensuring a continuous influx of top-tier talent. Looking ahead, we aim to establish a “BT+IT” emerging industry research institute to drive talent and industry clustering.

Our current infrastructure includes R&D centers in Hangzhou and Shenzhen, multiple medical testing centers nationwide, and an internet hospital in development. We are also in the process of applying for multiple medical device registration certificates to support the large-scale production, manufacturing, and certification of our innovative clinical products. As a leader in the field, OMIX aspires to be among the first global companies to secure regulatory approval for “multi-cancer” and complex disease early detection technologies. We anticipate serving millions of people annually, contributing billions of RMB in revenue, with a valuation exceeding $1 billion USD, while comparable U.S. companies have already reached a valuation of $8 billion USD. With a clear growth trajectory, we are targeting an IPO within the next five to seven years, aiming for a listing on the Sci-Tech Innovation Board or the Hong Kong Stock Exchange.